Trademark assistance
With qualifications and registrations in Australia and New Zealand, we offer a comprehensive range of trade mark services from initial clearance searches and filing strategies, drafting applications and acting in office actions, through to providing advice and litigation regarding registered and unregistered trade marks. In addition to trademark registration, we can assist with trademark renewals.
We work with trade mark attorneys around the world to ensure clients brands are strong, well protected, and compliant with INN naming conventions and policies.
With offices in Sydney, Melbourne and Brisbane our expert, award winning team can assist you or your client with their trademark or trade marking needs in the Australian & NZ jurisdictions.
![](https://www.pearceip.law/wp-content/uploads/2022/04/shutterstock_311457122-scaled-e1646704573899.jpg)
Contact us to discuss your trade mark
needs today.
![Pearce IP BioBlast® for w/e 19 July 2024](https://www.pearceip.law/wp-content/uploads/2024/07/LINKEDIN-FIRM-NEWS-POST-36-1080x627.png)
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that the European Medicines Agency (EMA) accepted its marketing authorisation applications (MAAs) for its...
![How to Handle Roadblocks with an Australian Patent Examiner](https://www.pearceip.law/wp-content/uploads/2024/07/Pearce-IP-Blog-How-to-Handle-Roadblocks-with-an-Australian-Patent-Examiner-1080x627.png)
How to Handle Roadblocks with an Australian Patent Examiner
How to Handle Roadblocks with an Australian Patent Examiner
Apple Inc. [2024] APO 25 (25 June 2024)
Amazentis SA [2024] APO 27 (28 June 2024)
![Pearce IP BioBlast® for w/e 19 July 2024](https://www.pearceip.law/wp-content/uploads/2024/07/LINKEDIN-FIRM-NEWS-POST-36-1080x627.png)
Pearce IP BioBlast for w/e 12 July 2024
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's Disease On 11 and 12 July 2024, respectively, Eisai and Biogen announced that Leqembi™ (lecanemab)...
Our Award Winning Firm
Women in Law Awards (Lawyers Weekly)
Winner – Partner of the Year (SME Law): Naomi Pearce (2021)
Shortlisted – Boutique Diversity Firm of the Year (2022)
Partner of the Year Awards (Lawyers Weekly)
Finalist – Intellectual Property: Naomi Pearce (2022)
World Intellectual Property Review (WIPR) WIPR Diversity
WIPR Diversity Champion in IP: Naomi Pearce (2022)
Top 100 Influential Women in IP: Naomi Pearce (2021)
Women in Business Law Awards – APAC
Winner – Patent Lawyer of the Year: Naomi Pearce (2022)
Shortlisted – Australian Firm of the Year (2022)
Shortlisted – Life Science Lawyer of the Year – Naomi Pearce (2022)